Nearly a decade later, taking the center stage at ASCO 2026, Akeso’s ivonescimab made history by offering the first-ever ...

In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard ...

SanDisk: 4,000% Not Enough? When it comes to the performance of SanDisk, Micron, and other stocks, we are slowly running out of superlatives. Take SanDisk, for example: 60% in one month, 600% in six ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BioNTech, once celebrated for its COVID-19 vaccines, is grappling with falling demand, restructuring and the departure of its founders. Can its ambitious cancer trials turn it from a one-hit wonder ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BioNTech has said it will halt COVID-19 vaccine manufacturing, targeting annual savings of around €500 million, and hand responsibility for producing the shots to its partner Pfizer. The announcement ...

BioNTech BNTX1.33%increase; green up pointing triangle plans to shrink its workforce and manufacturing network, as the German biotech company seeks to cut costs and downsize its footprint after demand ...

The German company that pioneered one of the first mRNA coronavirus vaccines is halting production, handing the reins to partner Pfizer. BioNTech is restructuring to focus on research and illnesses ...

Welcome to BioNTech's Fourth Quarter and Full Year 2025 Earnings Call. I will now hand the call over to Doug Maffei, Vice President, Strategy, Investor Relations. Please go ahead. Thank you, operator.

CEO Ugur Sahin highlighted that BioNTech maintained its leadership in the COVID vaccine market, launching a variant-adapted vaccine in partnership with Pfizer, now distributed in over 180 countries ...

BioNTech SE’s founders will leave the company to start a new biotech focused on messenger RNA, the technology behind their blockbuster Covid-19 vaccine, dashing investors’ confidence in the firm’s ...